TAIPEI, Taiwan, April 30, 2026 (GLOBE NEWSWIRE) — YD Bio Limited (“YD Bio” or the “Company”) (Nasdaq: YDES), a biotechnology company advancing DNA methylation-based cancer detection technology and ophthalmologic innovations, today announced its financial results for the full year ended December 31, 2025. Management Commentary“2025 was a highly transformative and foundational year for YD Bio, characterized by the successful capitalization of our long-term strategic vision. The successful completion of our business combination with Breeze Holdings Acquisition Corp. in August 2025, alongside a $13.2 million private investment in public equity (PIPE) financing, helped to significantly strengthen our balance sheet. Furthermore, we achieved a 17% increase in net revenue, driven predominantly by expanded pharmaceutical sales volumes and...

CALGARY, Alberta, April 30, 2026 (GLOBE NEWSWIRE) — Black Diamond Group Limited (“Black Diamond”, the “Company” or “we”), (TSX:BDI), a leading provider of space rental and workforce accommodation solutions, today announced its operating and financial results for the three months ended March 31, 2026 (the “Quarter”) compared with the three months ended March 31, 2025 (the “Comparative Quarter”). All financial figures are expressed in Canadian dollars. Key Highlights from the QuarterConsolidated revenue for the Quarter of $130.0 million and Adjusted EBITDA1 for the Quarter of $32.0 million increased 27% and 21%, respectively, from the Comparative Quarter. Consolidated rental revenue for the Quarter of $43.8 million increased 16% from the Comparative Quarter. The Company’s...

Netanya, Israel, April 30, 2026 (GLOBE NEWSWIRE) — Silynxcom Ltd. (NYSE American: SYNX) (“Silynxcom” or the “Company”), a manufacturer and developer of ruggedized tactical communication headset devices, today has released its consolidated financial results for the full year ended December 31, 2025, together with a strong business update for the beginning of 2026. Nir Klein, Chief Executive Officer of Silynxcom, commented: “In 2025, we acted strategically and proactively to expand the presence and brand awareness of Silynxcom in new markets. We established strategic relationships with new distributors, agents and resellers and significantly strengthened our global channel network. We laid a solid foundation in many countries across Asia and reinforced our existing relationships in additional markets worldwide....

On track for first patient dosed in phase 1/2 clinical trial evaluating CYWC628 in diabetic foot ulcers in Q2 of 2026 HOUSTON, April 30, 2026 (GLOBE NEWSWIRE) — FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today reported financial results for the first quarter ended March 31, 2026, and provided a corporate update. Recent Highlights Completed manufacturing of the first two batches of the CYWC628 drug product in accordance with Food & Drug Administration (FDA) Good Manufacturing Practices (cGMP) for the phase 1/2 clinical trial for the treatment of diabetic foot ulcers (DFUs). Completed site onboarding...

Planegg/Martinsried, Germany, April 30, 2026 – Leo International Precision Health AG (“LIPH” or the “Company”, ticker symbol: LEOW), a holding company building a global integrated AI-driven healthcare ecosystem, today published its consolidated financial results for the financial year 2025. The reporting year marked a transformational phase in the Company’s inception and development, establishing the structural, operational and strategic foundation for its growth strategy. 2025 HighlightsSuccessful listing in the General Standard of the Frankfurt Stock Exchange by means of a reverse takeover of SPOBAG AG establishing LIPH as a publicly listed precision health platform. Acquisition of six majority shareholdings forming the operational foundation of the Group’s integrated precision healthcare ecosystem in December 2025; with current valuation...

Diluted earnings per share (“EPS”) of $0.57 Invested $21 million in water and wastewater utility infrastructure during the three months ended March 31, 2026 Declared $0.36 common stock cash dividendISELIN, N.J., April 30, 2026 (GLOBE NEWSWIRE) — Middlesex Water Company (“Middlesex” or the “Company”) (NASDAQ: MSEX) today announced financial results for the first quarter ended March 31, 2026. “Our first-quarter results reflect disciplined execution across our operations, capital program, and regulatory strategy,” said Nadine Leslie, Chair, President and Chief Executive Officer of Middlesex Water Company. “We remain focused on delivering reliable service, investing strategically for long-term growth, and advancing our MWC 2030 Vision. This performance underscores the strength of our fundamentals and the dedication of our employees...

(All amounts expressed in U.S. dollars unless otherwise noted) VANCOUVER, British Columbia, April 30, 2026 (GLOBE NEWSWIRE) — Eldorado Gold Corporation (“Eldorado”, “Eldorado Gold” or “the Company”) (TSX: ELD) (NYSE: EGO) today reports the Company’s financial and operational results for the first quarter of 2026. For further information please see the Company’s Consolidated Financial Statements and Management’s Discussion and Analysis (“MD&A”) filed on SEDAR+ at www.sedarplus.com under the Company’s profile. First Quarter 2026 Highlights OperationsGold production: 100,358 ounces. Gold sales: 100,619 ounces at an average realized gold price per ounce sold(1) of $4,891. Production costs: $188.2 million Total cash costs(1): $1,470 per ounce sold All-in sustaining costs (“AISC”)(1): $1,942...

VANCOUVER, British Columbia, April 30, 2026 (GLOBE NEWSWIRE) — Rakovina Therapeutics Inc. (“Rakovina” or the “Company”) (TSX-V: RKV) (FSE: 7J0), a biopharmaceutical company advancing next-generation cancer therapies through artificial intelligence (AI)-powered drug discovery, today announced its financial results for the fourth quarter and fiscal year ended December 31, 2025, and provided a corporate update. As Rakovina enters 2026, the Company is advancing its three primary drug discovery programs toward key value-creating milestones. For kt-5000, lead optimization continues with Variational AI, with lead candidate selection and IND-enabling studies targeted for the second half of 2026. For kt-3283, in vivo ADME and efficacy testing of the LNP formulation is underway with NanoPalm. For kt-2000, a second round of AI output and in...

WISeKey Reports Audited Full Year 2025 Financial Results Schedules Conference Call for Monday, May 4 at 9:00am EDTAudited FY 2025 revenue of $19.3 million, representing 62% growth year-over-year Subsidiary SEALSQ reported 66% year-over-year revenue growth Reaffirms FY 2026 guidance with revenue expected to grow between 50%-100% year-over-year; Q1 2026 unaudited revenue of $4.2 million Strong cash and short-term investments of over $535 million as of April 30, 2026, well positions the WISeKey Group to execute growth strategy Commercial pipeline exceeding $200 million for 2026–2029 for SEALSQ alone, including over $60 million linked to QS7001 and QVault TPM programsGeneva, Switzerland – April 30, 2026 – Ad hoc announcement pursuant to Art. 53 LR – WISeKey International Holding Ltd (“WISeKey” or “WISeKey Group”) (SIX:...

NEWPORT BEACH, Calif., April 30, 2026 (GLOBE NEWSWIRE) — CV Holdings, Inc. (OTC Pink Limited: CVHL) (the “Company”) today reported a net loss for the year ended December 31, 2025 of $(16,241,821) or $(0.25) per common share with weighted average common shares of 64,413,784 issued and outstanding during 2025. The net loss was also $(0.25) per diluted common share based on 64,413,784 common shares outstanding on a fully-diluted basis. The net loss for the year ended December 31, 2025 was primarily due to interest expense on preferred equity of $16,166,901 as well as the Company’s credit loss expense of $7,357,049 and interest on line of credit of $7,768,609. Salaries and related payroll expenses were $7,601,740 and general and administrative expenses were $3,993,494. For comparative purposes, for the year ended December 31, 2024,...